Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
60Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-4.00M | $-0.05 |
| 2024 | $0.00 | $-13.19M | $-0.30 |
| 2023 | $0.00 | $-6.76M | $-0.17 |
| 2022 | $0.00 | $-7.34M | $-0.20 |
| 2021 | $0.00 | $-2.86M | $-0.11 |
Social Signal Score
Valuation
DTCFFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsnewsfilecorp.com·5h ago·Negative
… Chief Operating Officer and Head of Radiopharmaceutical Programs Montreal, Quebec--(Newsfile Corp. - August 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the appointment of Ryan Simms, PhD, as Chief Operating Officer ("COO") and Head of Radiopharmaceutical Programs, strengthen…
View source ↗